Overview
SYRE market data
Price History
SYRE price chart · 1M
- O
- 91.93
- H
- 94.74
- L
- 91.93
- C
- 94.04
- Vol
- 37,646.00
- Source
- US equities market feed
- Observed
- Aug 27, 2026, 12:00 AM
- Cadence
- Five-minute page cache; daily and stored hourly bars
- Status
- fresh
Key Stats & Performance
- Open
- $91.93
- Previous Close
- $93.74
- Day High
- $94.74
- Day Low
- $91.93
- 52 Week High
- $110.14
- 52 Week Low
- $64.75
- 7 Day Return
- -12.78%
- 30 Day Return
- -5.96%
- 90 Day Return
- +27.96%
- 1 Year Return
- +30.94%
- Daily Notional Volume
- $3.5M Latest daily bar volume multiplied by its closing price.
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$2.42 Diluted earnings per share over the trailing twelve months.
- Beta
- 3.06 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -22,158.5% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $14.51 – $110.18 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $9B · P/B 3.55 · P/S 7,296.20.
Company News
Deutsche Bank Maintains Buy on Spyre Therapeutics, Lowers Price Target to $127Benzinga · Aug 26, 2026, 6:01 PM
Spyre Therapeutics Says Rheumatoid Arthritis Program Misses Internal Benchmark, Stock TumblesBenzinga · Aug 26, 2026, 2:46 PM
Wedbush Maintains Outperform on Spyre Therapeutics, Lowers Price Target to $123Benzinga · Aug 26, 2026, 12:38 PM
Intuit, Zoom, Qfin Holdings And Other Big Stocks Moving Lower In Wednesday’s Pre-Market SessionBenzinga · Aug 26, 2026, 12:01 PM
Spyre Therapeutics shares are trading lower after the company announced topline results from the RA sub-study of its Phase 2 SKYWAY basket trial evaluating SPY072 in rheumatic diseases. The results did not meet the company's internal bar to prioritize advancement of SPY072 in RA.Benzinga · Aug 26, 2026, 11:47 AM
BTIG Maintains Buy on Spyre Therapeutics, Lowers Price Target to $121Benzinga · Aug 26, 2026, 10:01 AM
Why JOYY Shares Are Trading Higher; Here Are 20 Stocks Moving PremarketBenzinga · Aug 26, 2026, 9:22 AM
8-K filing — Spyre Therapeutics, Inc. (SYRE)SEC EDGAR · Aug 25, 2026, 8:04 PM
Spyre Therapeutics Says Both Doses Of SPY072 Met Statistical Significance On One Or More Endpoints In Phase 2 SKYWAY Rheumatoid Arthritis Sub-Study; Says Effect Did Not Meet Its Bar To Prioritize Monotherapy Development In RABenzinga · Aug 25, 2026, 8:02 PM
Target To Rally Around 12%? Here Are 10 Top Analyst Forecasts For TuesdayBenzinga · Aug 11, 2026, 11:59 AM